Luye Pharma Group Co., Ltd.
| Brand name |
LU YE ZHI YAO.
|
| Main products |
Pharma |
| Annual sales |
USD 1,000,000,000.00 |
| Date of establishment |
1994-10-15 |
| Number of employees |
1000 Persons |
| Number of R&D staff |
40 Persons |
| Number of quality inspectors |
25 Persons |
| Area of factory |
100000 ㎡ |
Luye
Pharma Group Co., Ltd.is a professional pharmaceutical enterprise
built on a solid foundation of research and development and
focusing on the largest and fastest growing therapeutic
areas——oncology, cardiovascular system, alimentary tract and
metabolism, and central nervous system. The company was founded in
1994 and listed on the main board of the Hong Kong Stock Exchange
in 2014 (02186.HK). The company has state-of-the-art production
facilities located in Yantai, Nanjing, Beijing and Luzhou; as well
as overseas branch offices in Hong Kong, USA, Singapore and
Malaysia. Thecompany has approximatly 4,000 employees, including
close to 300 R&D specialists and over 1,300 sales and
marketing personnel.
Luye
Pharma is focused on the R&D and manufacture of innovative
pharmaceutical products, and is among the earliest Chinese
pharmaceutical enterprises to conduct clinical trials in the
mainstream international market. Currently, Luye Pharma has
multiple innovative preparations and drugs that are undergoing
different stages of registry clinical studies in FDA, and as
breakthroughs achieved, it is expected to be the first Chinese
pharmaceutical enterprise that launches new drugs in the USA. In
July, 2016, Luye Pharma announced its agreement to acquire the
advanced transdermal drug delivery systems (TDS) business from
Acino, a Europe based global leader and manufacturer of TDS, to
further strengthen its advantage in the area of controlled release technology.
Luye
Pharma has evolved into a leading innovation-oriented
pharmaceutical enterprise in China. On the back of innovation and
internationalization; the company will endeavor to become one of
the top 100 global pharmaceutical companies by 2020.
Brief Introduction
Luye
Pharma Group Co., Ltd.is a professional pharmaceutical enterprise
built on a solid foundation of research and development and
focusing on the largest and fastest growing therapeutic
areas——oncology, cardiovascular system, alimentary tract and
metabolism, and central nervous system. The company was founded in
1994 and listed on the main board of the Hong Kong Stock Exchange
in 2014 (02186.HK). The company has state-of-the-art production
facilities located in Yantai, Nanjing, Beijing and Luzhou; as well
as overseas branch offices in Hong Kong, USA, Singapore and
Malaysia. Thecompany has approximatly 4,000 employees, including
close to 300 R&D specialists and over 1,300 sales and
marketing personnel.
Luye
Pharma is focused on the R&D and manufacture of innovative
pharmaceutical products, and is among the earliest Chinese
pharmaceutical enterprises to conduct clinical trials in the
mainstream international market. Currently, Luye Pharma has
multiple innovative preparations and drugs that are undergoing
different stages of registry clinical studies in FDA, and as
breakthroughs achieved, it is expected to be the first Chinese
pharmaceutical enterprise that launches new drugs in the USA. In
July, 2016, Luye Pharma announced its agreement to acquire the
advanced transdermal drug delivery systems (TDS) business from
Acino, a Europe based global leader and manufacturer of TDS, to
further strengthen its advantage in the area of controlled release technology.
Luye
Pharma has evolved into a leading innovation-oriented
pharmaceutical enterprise in China. On the back of innovation and
internationalization; the company will endeavor to become one of
the top 100 global pharmaceutical companies by 2020.
Send your message to this factory
